6DDECEMBER- MARCHTECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThere's a shift toward more collaborative and technologically integrated approaches in clinical trials. The convergence of computational power with scientific experimentation stands out as a prominent trend, opening new frontiers in drug discovery and development. The impact of this trend is particularly evident in AI-mediated drug discovery, where investments have soared, reaching $2.5 billion this year. Generative AI (GenAI) is another pivotal trend reshaping the biopharma industry. Nearly 40 percent of life sciences work hours are expected to be influenced by GenAI. Its applications span a wide range, from antibody design and protein structure prediction to the generation of digital marketing content and production planning optimization. This shift toward AI-driven processes signifies a major transformation in how biopharma companies operate, making processes more efficient and innovation-driven. Driven by these trends, the global pharmaceutical outsourcing services market size is expected to grow at a CAGR of 5.3 percent from 2023 to 2030. This edition of Pharma Tech Outlook APAC brings insights into the latest developments in pharmaceutical outsourcing.It features a thought leadership article from Rhona Macdonald, Head of Clinical Research at Douglas Pharmaceuticals, who sheds light on specialization in generic and repurposed drugs. The magazine also features an article by Ming Li, Director of Bioanalytical and Biomarker Outsourcing Operations at Alexion Pharmaceuticals, who educates us on how AI can change the field of bioanalysis.We also bring to you top pharmaceutical outsourcing service providers delivering innovative solutions that give organizations a competitive advantage and help them make informed decisions. A noteworthy story is that of Jianshun Biotech. This well-established company is a first-class leader in cell culture technology and a supplier of high-quality cell culture media products.This edition presents you with two other compelling stories. One is Libra Medicina. Its role as an intermediary licensing firm is critical for meeting various outsourcing demands within the life sciences industry, enabling projects to outsource efficiently and effectively. PPD-SNBL, on the other hand, stands out as a partner supporting leading pharma clients in Japan, offering comprehensive services from initial consultation through the complex phases of clinical development, thereby contributing significantly to the advancement of pharmaceuticals.In this edition featuring the Top 10 Pharmaceutical Outsourcing Services Providers in APAC 2023, we hope you find the right partner to meet your organization's needs.Let us know your thoughts!The Rising Tide of AI in Pharmaceutical OutsourcingCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - MARCH, Vol 10 - Issue 01 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Edwin PaulTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >